NCT07387549

A Study to Assess How Well and Safely Elafibranor Works in Adult Participants With Primary Sclerosing Cholangitis

RecruitingPHASE3INTERVENTIONAL

Trial Details

Start: 2026-05-14Est. Completion: 2031-04-30

Enrollment target: 350 participants

Locations

Arizona Liver Health, Chandler, Arizona, United States
Mayo Clinic in Arizona, Phoenix, Arizona, United States
Southern California Research Center, Coronado, California, United States
University of California San Diego, La Jolla, California, United States
Keck Medicine of USC - USC Healthcare Center 1, Los Angeles, California, United States
Cedars-Sinai Medical Center, Los Angeles, California, United States
California Liver Research Institute, Pasadena, California, United States
Stanford University, Redwood City, California, United States
University of California Davis Medical Center, Sacramento, California, United States
Sutter Health Van Ness Campus Medical Office Building, San Francisco, California, United States
University of California, San Francisco Medical Center, San Francisco, California, United States
University of Colorado Hospital Anschutz Outpatient Pavilion, Aurora, Colorado, United States
Peak Gastroenterology Associates, Colorado Springs, Colorado, United States
South Denver Gastroenterology,P.C., Englewood, Colorado, United States

Primary Sclerosing Cholangitis

This study will evaluate the effects of elafibranor (the study drug) in participants with Primary Sclerosing Cholangitis…

Lancaster, United StatesEst. completion Sep 23, 2031

Primary Sclerosing Cholangitis

To find out if vancomycin is a safe and effective therapy for primary sclerosing cholangitis. Funding Source - FDA OOPD

Phoenix, United StatesCompleted Mar 3, 2025

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.